期刊文献+

索拉非尼治疗原发性肝癌的不良反应分析 被引量:3

Adverse reactions of using sorafenib in primary liver cancer
下载PDF
导出
摘要 目的分析索拉非尼在国人中治疗原发性肝癌患者过程中出现的不良反应的特征。方法对在该科应用索拉非尼治疗原发性肝癌的30例患者的各种可能与应用索拉非尼有关的不良反应进行分级、记录与统计分析。结果观察到患者出现的与服用索拉非尼有关的不良反应主要为手足综合征、血压升高、脱发、腹泻、疲乏等。结论国人应用索拉非尼患者手足综合征、高血压、腹泻的发生率较高,亦可观察到骨髓抑制及肾功能损害,不良反应一般为轻中度,患者大多可以耐受,不需特殊处理。对于部分严重不良反应,予以停药或对症处理后均恢复正常。 Aim To analyze the molecular target drug sorafenib treatment of primary liver cancer in patients with adverse events arising in the course of the characteristics.Methods Data of 30 cases of application of sorafenib treatment of primary liver cancer in patients which may be related to a variety of sorafenib-related adverse events were graded,recorded and statistically analyzed.Results The adverse events were mainly hand-foot syndrome,high blood pressure,hair loss,diarrhea,fatigue and so on.Conclusion Bone marrow suppression can also be observed and renal function impairment in patients with hand-foot syndrome,high blood pressure,and high incidence of diarrhea.Adverse reactions are generally mild to moderate,and patients are mostly tolerated,without special treatment.For some serious adverse reactions,it can return to normal through the interruption of treatment or symptomatic treatment.
作者 闫敏 潘跃银
出处 《安徽医药》 CAS 2010年第9期1066-1068,共3页 Anhui Medical and Pharmaceutical Journal
基金 安徽省科技厅重点项目(No07020304102)
关键词 索拉非尼 原发性肝癌 不良反应 sorafenib primary liver cancer adverse reaction
  • 相关文献

参考文献2

二级参考文献12

共引文献89

同被引文献32

  • 1管考鹏,马建辉,孙燕.索拉非尼的毒副作用及处理[J].癌症进展,2007,5(4):370-373. 被引量:39
  • 2Llovet JM, Bru C, Bruix J. Prognosis of hepatocel- lularcarcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999,19(3):329-338.
  • 3Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome[J]? Eur J Cancer, 2006, 42(4): 548-556.
  • 4Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006[J]. J Clin Onco, 2006, 24(9):1363-1369.
  • 5Llovet J,Ricci S,Mazzaferro V,et al. Sorafenib in advanced nepatocellular Carcinoma[J].N Engl J Med, 2008,35(4):378-390.
  • 6Cheng AL,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:Subset analyses of the phase Ⅲ S rafenib asia-pacific trial [J].Eur J Cancer 2012,doi:10. 1016/j. ejca,2011,12,006.
  • 7王雄文,陈日辉.索拉非尼配合辨证中药汤剂治疗晚期原发性肝癌18例临床观察[J].中国医药导报,2008,5(35):48-49. 被引量:7
  • 8周爱萍,何志嵩,于世英,张沂平,杜春霞,孙永昆,石远凯,王金万,那彦群,孙燕.索拉非尼治疗转移性肾癌的临床研究[J].中华泌尿外科杂志,2009,30(1):10-14. 被引量:54
  • 9杨秉辉,丛文铭,周晓军,陈孝平,杨甲梅,樊嘉,王建华,杨仁杰,李槐,蒋国梁,曾昭冲,陈敏华,陈敏山,梁萍,吕明德,罗荣城,刘鲁明,秦叔逵,叶胜龙,吴孟超,汤钊猷,孙燕,管忠震.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269. 被引量:310
  • 10刘淼,陈红鸽,吴荣荣,魏振满.索拉非尼治疗肝癌的研究进展[J].医药导报,2009,28(12):1562-1564. 被引量:6

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部